Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
First Claim
Patent Images
1. A method of reducing cholesterol level or maintaining previously reduced cholesterol level in a human in need thereof, the method comprising administering to said human an antibody or antibody fragment that specifically binds a proprotein convertase subtilisin/kexin type 9 (PCSK9) that comprises a C-terminal domain comprising a mutation selected from the group consisting of I474V and E670G in SEQ ID NO:
- 1,wherein the antibody or antibody fragment comprises a VH domain derived from the recombination of a human VH segment, a human D gene segment and a human JH segment, the human VH segment encoding the framework 1 of SEQ ID NO;
40, and wherein said human comprises;
(i) a VH gene segment encoding the framework 1 of SEQ ID NO;
40, or the human expresses antibodies comprising VH domains derived from the recombination of a human VH segment, a human D gene segment and a human JH segment, the human VH segment encoding the framework 1 of SEQ ID NO;
40; and
(ii) a nucleotide sequence encoding said PCSK9 that comprises a C-terminal domain comprising said selected mutation in SEQ ID NO;
1.
1 Assignment
0 Petitions
Reexamination
Accused Products
Abstract
The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
121 Citations
26 Claims
-
1. A method of reducing cholesterol level or maintaining previously reduced cholesterol level in a human in need thereof, the method comprising administering to said human an antibody or antibody fragment that specifically binds a proprotein convertase subtilisin/kexin type 9 (PCSK9) that comprises a C-terminal domain comprising a mutation selected from the group consisting of I474V and E670G in SEQ ID NO:
- 1,
wherein the antibody or antibody fragment comprises a VH domain derived from the recombination of a human VH segment, a human D gene segment and a human JH segment, the human VH segment encoding the framework 1 of SEQ ID NO;
40, and wherein said human comprises;(i) a VH gene segment encoding the framework 1 of SEQ ID NO;
40, or the human expresses antibodies comprising VH domains derived from the recombination of a human VH segment, a human D gene segment and a human JH segment, the human VH segment encoding the framework 1 of SEQ ID NO;
40; and(ii) a nucleotide sequence encoding said PCSK9 that comprises a C-terminal domain comprising said selected mutation in SEQ ID NO;
1. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
- 1,
Specification